On August 3, 2025, HeartSciences Inc. amended its Equity Distribution Agreement to allow the sale of up to $25 million in common stock, increasing from a previous $15 million allowance. The amendment also sets commission rates for Maxim Group at 4.0% up to $11,036,310 in sales, and then 3.0% thereafter.